News
BDTX
2.990
+9.93%
0.270
Analysts Are Bullish on Top Healthcare Stocks: Pacific Biosciences (PACB), 20/20 Biolabs, Inc. (AIDX)
TipRanks · 2d ago
Wedbush Reaffirms Their Buy Rating on Black Diamond Therapeutics (BDTX)
TipRanks · 2d ago
Analyst Reiterates Buy on Black Diamond Therapeutics, Citing Differentiated EGFR Inhibitor and Strong Cash Runway Through 2028
TipRanks · 3d ago
Best Small Cap Value Stocks May 2026
Seeking Alpha · 3d ago
Black Diamond Therapeutic Q1 EPS $(0.16) Misses $(0.03) Estimate
Benzinga · 3d ago
Black Diamond Therapeutics GAAP EPS of -$0.16 beats by $0.02
Seeking Alpha · 3d ago
BLACK DIAMOND THERAPEUTICS: Q1 EPS $-0.16
Reuters · 3d ago
*Black Diamond Theraptcs 1Q Loss/Shr 16c >BDTX
Dow Jones · 3d ago
Press Release: Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Dow Jones · 3d ago
Press Release: Black Diamond Therapeutics Reports -2-
Dow Jones · 3d ago
Black Diamond Therapeutics turns to Q1 net loss of $9 million
PUBT · 3d ago
Black Diamond Therapeutics Q1 FY26 net loss widens to $9.04 million; no revenue
PUBT · 3d ago
Black Diamond: Q1 Earnings Snapshot
Barchart · 4d ago
Weekly Report: what happened at BDTX last week (0427-0501)?
Weekly Report · 6d ago
Olema appoints Prakash Raman to board of directors
PUBT · 04/29 20:05
Black Diamond Theraptcs Is Maintained at Buy by BTIG
Dow Jones · 04/29 10:45
Black Diamond Theraptcs Price Target Raised to $11.00/Share From $10.00 by BTIG
Dow Jones · 04/29 10:45
BTIG Maintains Buy on Black Diamond Therapeutic, Raises Price Target to $11
Benzinga · 04/29 10:38
Black Diamond price target raised to $11 from $10 at H.C. Wainwright
TipRanks · 04/29 10:21
U.S. RESEARCH ROUNDUP-Coca-Cola Co, Mondelez, Zeta Global Holdings
Reuters · 04/29 08:01
More
Webull provides a variety of real-time BDTX stock news. You can receive the latest news about Black Diamond Therapeutics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About BDTX
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.